



INDUSTRY SUPPORTER PRODUCT GUIDE

Agendia

Agendia is a leading provider of innovative precision oncology solutions for early-stage breast cancer. Using advanced genomic assays like MammaPrint® and Blueprint®, they enable clinicians to quickly identify the most effective treatment plan, minimizing risks of over- and undertreatment. Led by renowned scientists and oncologists, Agendia is dedicated to advancing genomic insights through ongoing research. Their FLEX Study, the world's largest Real-World Evidence-based Breast Cancer database, aims to revolutionize precision in breast cancer management. With cutting-edge technology and a commitment to innovation, Agendia strives to shape the future of precision oncology and combat breast cancer effectively.

- **MammaPrint® + Blueprint® genomic assays for early-stage breast cancer:**
- **MammaPrint (70-gene assay):**
 - MammaPrint is a FDA-cleared, gene expression profiling test assess a woman's risk of distant metastasis with early-stage breast cancer
 - MammaPrint provides critical answers that inform the future of woman's treatment plans at the point of diagnosis, including the timing and benefit to chemotherapy and endocrine therapy
 - MammaPrint listens to the signals from 70 key genes in a woman's tumor to stratify her risk within four distinct categories- ranging from UltraLow, Low, High 1, and High 2– to fuel a right-sized care plan tailored to her biology and her life's plans.
- **Blueprint (80-gene assay):**
 - Blueprint is a gene expression profiling test that reveals the driving forces behind a tumor's growth at the earliest stage possible in a woman's breast cancer care journey to optimize and personalize treatment planning.
 - Blueprint goes where pathology cannot, offers critical insights that providers may otherwise have not known to act on, and gives women the best chance to return to a life not defined by cancer.

- Blueprint measures the activity of 80 key genes that are involved in a tumor's growth to classify a tumor as Luminal-type, HER2-type, or Basal-type, each of which warrant distinct treatment pathways.
- By revealing the distinct underlying biology of a woman's tumor, Blueprint can catch often misclassified, yet highly aggressive, Basal tumors, so women can be prescribed the most appropriate treatment from the start.
- **Product/Informational Video link:** <https://youtu.be/HojpUzzYuk0?si=AKQOes0eZkW5pUFY>

Company Contact Information:

For more information or to speak with a local representative about MammaPrint + Blueprint, please visit: <https://agendia.com/contact-us/> or contact us via email or phone: customercare@agendia.com, (888)-321-2732

Follow us on **Social Media** for updates and announcements:

- [LinkedIn](#)
- [Twitter](#)
- [Facebook](#)
- Instagram: Agendiainc
- [YouTube](#)

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Jennifer Hayes, PhD, Medical Lead, DDR Breast
US Medical Affairs Oncology, AstraZeneca
jennifer.hayes1@astrazeneca.com
202-445-4878

Cardinal Health

At Cardinal Health Nuclear & Precision Health Solutions, we provide essential products and services that support nuclear medicine providers in caring for their patients. Our portfolio of radiopharmaceuticals includes agents used in lymphatic mapping and guiding sentinel lymph node biopsies in patients with breast cancer.

We are proud to offer **LYMPHOSEEK®**, the first and only agent specifically designed for receptor targeted lymphatic mapping and guiding sentinel lymph node biopsy.

Select Important Safety Information:

LYMPHOSEEK® is a radioactive drug and should be handled by or under the control of qualified and licensed physicians with appropriate safety measures to help decrease radiation exposure. Any radiation-emitting product may increase the risk for cancer, especially in pediatric patients. Adhere to the dose recommendations and ensure safe handling to decrease the risk for excessive exposure to either patients or health care workers.

In clinical trials with LYMPHOSEEK®, no serious hypersensitivity reactions were reported, however LYMPHOSEEK® may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Please see full [Prescribing Information](#) for additional information.

Website: www.lymphoseek.com

Mechanism of action video: https://www.lymphoseek.com/en_us/about-lymphoseek/mechanism-of-action.html

Company Contact Information:

- Kevin King – kevin.king@cardinalhealth.com
- Melissa Hirt – melissa.hirt@cardinalhealth.com
- Medical Affairs – npsmedicalinfo@cardinalhealth.com

Follow us on [LinkedIn](#)

Endomag

At Endomag, we believe everyone deserves a better standard of cancer care – that’s why we design our cancer localization technologies with both the clinician and patient in mind. Many leading hospitals across the US use our unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.

Our Magseed® marker is a tiny, non-radioactive seed, ideal for accurately marking tumors and lymph nodes, while the Magtrace® lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping. Paired with the Sentimag® localization platform, they have now been widely proven across over 100 clinical studies, featuring more than 23,000 patients.

The Sentimag® platform, distributed by Mammotome in North America, has already helped 475,000+ women worldwide to access more precise and less invasive breast cancer treatment. Are you ready to join the magnetic revolution?

To find out more, visit www.endomag.com

Primary educational points about your product(s)

- Our Sentimag® platform works alongside the Magseed® marker and Magtrace® lymphatic tracer to support tumor and lymph node localization.

- These are alternative technologies to older solutions such as the guidewire and radioactive lymphatic tracers.
 - They have been proven across clinical studies, with over 12,000 patients featured in Magseed studies and over 11,000 in Magtrace studies.
 - Some of the most prominent papers featuring our technologies include [SentiMAGIC \(2019\)](#), [Simons et al \(2021\)](#), [iBRA-NET \(2022\)](#), [SentiNOT \(2023\)](#) and [Pantiora et al \(2023\)](#). The latter is the first randomized control trial for any wireless see marker.
 - The platform is unique in that can be used for many techniques, including lesion localization, sentinel lymph node biopsy, targeted axillary dissection, delayed sentinel lymph node biopsy, LYMPHA and the brand new MagTotal™ technique.
- **Product/Informational Video Links:**
 - [Animated explainer of the Delayed SLNB technique](#)
 - [Magnetic TAD surgery from UCSF](#)
 - **Company Information:** To find out more about our technologies, please contact us via email (info@endomag.com) or phone ([+1 \(512\) 872-2400](tel:+15128722400))

Exact Sciences

A leading provider of cancer screening and diagnostic tests, **Exact Sciences** relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline with the launch of the OncoExTra® and Riskguard® tests to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.

- **The Oncotype DX Breast Recurrence Score® test**

What it does:

The Oncotype DX Breast Recurrence Score® test is a genomic test for patients with early-stage (I, II, IIIa), hormone receptor positive, HER2-negative breast cancer that is node-negative or node-positive (1-3 nodes) that can help patients understand certain risks and benefits. The Oncotype DX Breast Recurrence Score test can help add clarity to treatment decisions by answering the following:

- 1) What is the risk of recurrence?
- 2) What is the absolute benefit of chemotherapy?

- **The Riskguard® test**

What it does:

The Riskguard® test is an assessment tool that can help uncover hereditary cancer risk. The actionable results can help you better understand your patients' cancer risks and management options supporting personalized care.

For more information, please visit the company's website at www.exactsciences.com.

Hologic, Inc.

Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include invention of the world's first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.

The company also champions women through the [Hologic Global Women's Health Index](#), which provides a science-backed data framework for improving women's well-being.

- **Hologic Products for breast surgery:**

- **LOCalizer™ Wire-free Guidance System** is designed to mark and guide to non-palpable breast lesions using a miniature radiofrequency identification (RFID) Tag. Each Tag has a unique identification number that is displayed on the reader and can be placed in the breast any time prior to or on the day of surgery. The Surgical Probe is a pencil-sized, single-use sterile probe that will guide the surgeon towards the Tag during the operation. The 8mm diameter of the probe allows for small incisions. The portable handheld Reader displays the distance to the Tag in millimeters and the Tag's ID number on a bright screen, making it easy to read during the procedure. The LOCalizer system can read the tag at up to a 60mm distance and is designed to function without interference from the other equipment in the OR.
- **Tuflex™ thread markers** facilitate intraoperative localization, distinguished by a flexible multi-wire design. Designed to decouple wire localization from surgery for up to 3 days, it provides greater flexibility and helps to eliminate same-day localization and surgery scheduling challenges. The markers can also be used for stereotactic, mammography, and ultrasound procedures. The marker is designed to anchor firmly in the tissue, made of 19 wires twisted together.
- **Tuloc™ monofilament marking wires** with double-hook anchor for non-palpable, suspicious breast abnormalities help facilitate pre-surgical wire localization. They are available for stereotactic, mammography and ultrasound modalities. The double hook expands upon deployment and anchors firmly in the tissue.
- Hologic's range of **Tumark® Biopsy Site Markers** come in multiple shapes, gauges and lengths, empowering physicians to individualize each patient's care. Our comprehensive selection of markers include options for use with stereotactic, ultrasound, and MRI guided biopsies. All markers come with an ergonomic and easy to use deployment device.
- **TruNode® single-use gamma probe** system enhances breast surgery as a high performance, sterile, single-use, wireless gamma probe. It is designed for the most common radio-guided surgical procedures, including sentinel lymph node biopsy.

The TruNode system is designed to detect faint nodes even when close to the injection site and enables precise hotspot localization throughout the axilla. Additionally, the sterile, single-use

nature of the probe reduces the risk of cross-contamination and surgical site infections by eliminating the need to re-process a reusable probe.

- **Trident® HD** is the only specimen radiography system to take advantage of amorphous selenium direct capture imaging to generate crisp, clear, high resolution biopsy images that inspire confidence. Automatic Exposure Control (AEC) is optimized for breast excisions and core biopsies. Trident HD offers instant verification which results in reduced procedure time and improved workflow. This intuitive user interface and software-driven controls eliminate steps, simplify staff communication, and encourage collaboration.
- **Product/Informational Video Links:**
 - [LOCalizer® Wire-free Guidance System \[youtube.com\]](#)
 - [Breast Surgery Wires](#)
 - [Tumark Biopsy Site Markers](#)
 - [TruNode® Single-use Gamma Probe System \[youtube.com\]](#)
 - [Trident® HD Specimen Radiography System \[youtube.com\]](#)
 - [Hologic Global Women's Health Index](#)
- **Company Contact Information:**
 - BSHmedicalaffairs@hologic.com
 - www.hologic.com/breast-health

Kubtec

At KUBTEC®, our passion is developing transformative technologies that enable precision surgery for breast cancer. For nearly 20 years, we have led the way in specimen imaging technology, and now offer the widest range of specimen radiography systems. Building on this legacy, we also provide an innovative gamma probe detection system that seamlessly integrates with our imaging solutions. As a family-owned company, headquartered in Connecticut, USA, our dedication to improving care goes beyond exceptional products - we take immense pride in delivering unparalleled service and support to all our customers across the globe.

Highlighted KUBTEC Products for Breast Surgery

The MOZART® iQ 3D Specimen Radiography System is a major advancement in intraoperative breast cancer margin assessment from KUBTEC. It uses 3D Tomosynthesis X-ray technology, the gold standard for diagnostic mammography, as well as amorphous selenium direct capture imaging technology, to enable surgeons to accurately detect positive margins in breast cancer patients undergoing segmental mastectomy. It also includes a wide range of innovative, proprietary workflow features designed to improve OR efficiency, such as Voice Control, Integrated HD Optical Camera, The Image Blender™, and a large imaging area.

MOZART® 3D tomosynthesis imaging technology has been shown in independent clinical studies, published in peer-reviewed journals, to deliver key benefits when used in the OR, including reduced re-excision rates, increased healthy breast tissue preservation, and improved efficiency.

- **Re-excisions:** In a UT Southwestern study of 446 breast cancer surgeries, The MOZART® System "**decreased re-excision rates by more than half**" compared to the Hologic Trident® System.

- **Tissue Preservation:** In a MD Anderson study of 99 breast cancer surgeries the authors concluded that use of The MOZART® System “decreases the amount of additional tissue excised unnecessarily.”
 - **Efficiency:** In a Rush Medical study, the use of The MOZART® system “saved an average of 7.6 minutes per surgery and a decrease in OR cost of \$284.62 per case” for wire-localized segmental mastectomies.
- Please click here to learn more about [The MOZART® iQ System](#)
 - Please click here to see a [product video for The MOZART® iQ System](#)
 - Please click here to see [MOZART® Clinical Evidence](#)

The GammaPRO® Gamma Detection System from KUBTEC is a modern, highly innovative gamma detection system optimized for today’s fast-paced clinical environment. The unique crystal technology at the heart of The GammaPRO® System is a pivotal advancement in probe design that sets a new standard for sensitivity and reliability. Its narrow tip, ease of use and maneuverability make The GammaPRO® System ideal for precision surgery. It is also the world’s first and only gamma probe to be fully integrated with intraoperative specimen imaging systems.

- Please click here to learn more about [The GammaPRO® Gamma Detection System](#)
- Please click here to see a [product video for The GammaPRO® System](#)

Please click here to learn more about the full [KUBTEC Portfolio for the OR](#)

Company Contact Information

To find out more about our technologies or other enquiries, please:

- Visit us at www.kubtec.com
- Email us at kubtec@kubtec.com or email Tom Siffringer at tsiffringer@kubtec.com
- Follow Us on [LinkedIn](#)

Mammotome

Brought to you by Mammotome, the experts in breast biopsy, the HydroMARK™ Plus Breast Biopsy Site Marker is the latest novel technology in axillary and breast lesion marking. Developed with surgeons in mind, the tissue marker offers confidence throughout your patient’s journey with a new dragonfly shape with “wings”.

HydroMARK™ Plus markers offer the same great benefits of the original HydroMARK™ markers with added features designed to alleviate displacement, enhance visibility, and ease of locating.

- **Primary Educational Points:**
 - “Wings” are designed to anchor to the tissue to mitigate displacement during surgical excision
 - Hydrates providing up to 12 months ultrasound visibility, even after neoadjuvant chemotherapy

- Allows for intraoperative localization of target tissue as well as ultrasound of the specimen, potentially eliminating the need for specimen radiograph
- **Product/Informational Video Links:**
 - <https://youtu.be/vpULU43IDYw?feature=shared>
- **Company Contact Information:**
 - Jodi Hafemeister, Director – Americans Marketing and Education
jodi.hafemeister@mammotome.com
mammotome.com

Merit Oncology

At Merit Oncology, we are committed to easing the burden that cancer places on patients and their loved ones by developing unparalleled technologies to improve the treatment process for patients and physicians.

SCOUT® Radar Localization is the first localization platform to use highly sophisticated radar technology to deliver precise, efficient localization and real-time surgical guidance for removal of breast and soft tissue tumors. SCOUT is the only localization device that can be placed at the time of biopsy of highly suspicious lesions due to its insignificant MRI artifact and minimal migration, sparing breast surgical patients a redundant procedure. The SCOUT Bx™ delivery system enables placement at biopsy under all imaging modalities – stereotactic, MRI and ultrasound. SCOUT®, the global leader in wire-free localization has been used in over 500,000 procedures and is referenced in over 90 clinical publications. Merit's latest innovation to the SCOUT platform is SCOUT MD™ - providing four unique reflector shapes with distinct RADAR signals, enabling more precise tumor margin mapping and localization of multiple lesions or nodes.

Easing the burden of breast cancer treatment, SAVI® Brachy offers a strut-based approach to tissue-sparing dosimetry and is designed to maximize ease of use during placement while providing unparalleled dose customization. Three-fraction treatment protocol with SAVI allows effective APBI treatment to be completed in as little as 2 days, significantly decreasing contact interactions between patients and medical staff.

- **Product/Informational Video Links:**

SCOUT® Radar Localization: <https://www.merit.com/product/scout-radar-localization/>

SCOUT MD™ – Taking SCOUT to a New Dimension: [Learn more](#)

SCOUT Bx™ – Localize under MRI Guidance & at Time of Biopsy: <https://www.merit.com/product/scout-bx/>

SCOUT® Mini Reflector: <https://www.merit.com/product/scout-mini-reflector/>

SCOUT Education: <https://www.merit.com/education/courses/thinkwirefree/>

SAVI® APBI: <https://www.merit.com/product/savi-brachy/>
- **Company Contact information:**

Jane Perry, Global Vice President, Marketing, jperry@merit.com

Stryker

- Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at <https://bit.ly/48hTLO0>
- **Primary educational points:**
 - Stryker's SPY Portable Handheld Imager (SPY-PHI) utilizes SPY Fluorescence Imaging technology and provides surgeons with a convenient, compact solution for real-time perfusion assessment in breast reconstruction and other open surgeries.
 - Our Illuminated Instruments enable greater visualization, ability, and precision during open surgery.
- **Product video links:**
 - https://youtu.be/eun_WYH44Ts?si=N01YA3T0BwMCuY_j
 - <https://youtu.be/QrG3SIXAPQg?si=8Vy8IS3CcvPOo6Wu>
- **Company Contact information:**
 - Alexis Giller, Alexis.giller@stryker.com, 661-645-2370, <https://bit.ly/48hTLO0>